| Income Statement | 2026-06-30 | |||
|---|---|---|---|---|
| Total revenues | 97 | |||
| Research and development | 788 | |||
| General and administrative | 2,411 | |||
| Total operating expenses | 3,199 | |||
| Operating loss | -3,102 | |||
| Other income, net | 203 | |||
| Loss from continuing operations before income taxes | -2,899 | |||
| Income tax expense | 0 | |||
| Loss from continuing operations | -2,899 | |||
| Loss from discontinued operations, net of income taxes | -108 | |||
| Net loss | -3,007 | |||
| Unrealized losses on marketable securities, net of tax of 0 | 0 | |||
| Total other comprehensive loss | 0 | |||
| Comprehensive loss | -3,007 | |||
| Basic EPS | -3.51 | |||
| Diluted EPS | -3.51 | |||
| Basic Average Shares | 858,000 | |||
| Diluted Average Shares | 858,000 | |||
Yarrow Bioscience, Inc. (YARW)
Yarrow Bioscience, Inc. (YARW)